A disputed usage definition can sound like a minor editorial problem until it becomes part of the case for a $15 billion company.
OpenEvidence's valuation is no longer merely a fundraising rumour. On 28 September 2026, Becker's reported confirmation from chief executive Daniel Nadler that the company had raised $250 million at a $15 billion valuation, with Andreessen Horowitz and Byers Capital leading the round.
That establishes a financing event. The harder question is what future business performance can justify the price. Physician adoption is central to that discussion because it helps explain distribution, repeated use and the commercial opportunities associated with a valuable professional audience.
The distinction between registered doctors and doctors actively using a product therefore belongs in the financial analysis. At this scale, the denominator is part of the investment thesis.
Keep the valuation arithmetic honest
Sacra estimates that OpenEvidence reached $300 million in annualised revenue in July 2026. That is an external estimate of a revenue rate, not an audited annual revenue figure. Dividing the reported $15 billion equity valuation by that estimate gives 50 times the annualised amount.
The calculation is simple. Its interpretation requires care with the inputs. Annualising a recent revenue period is different from measuring a completed financial year, and equity value divided by revenue is not a fully adjusted enterprise-value comparison.
The following scenarios are illustrative arithmetic, holding the valuation constant. They are not forecasts of OpenEvidence's results.
| Annual revenue or annualised revenue assumption | $15 billion divided by the assumption |
|---|---|
| $300 million | 50 times |
| $600 million | 25 times |
| $1 billion | 15 times |
The table shows why growth assumptions do so much work. A valuation that looks demanding against one revenue level can look very different against another. It does not tell us whether the larger figure will arrive, how much it will cost to generate or how durable it will be.
Those are the questions that a large adoption number is often invited to answer indirectly. It should instead be examined as one input among several.
Registered doctors cannot be spent
An account creates the possibility of a relationship. Commercial value depends on what happens afterwards.
For an advertising-supported service, a useful analytical chain runs from active users to relevant activity, then to eligible advertising opportunities, sold inventory and realised pricing. Sacra describes pharmaceutical and medical device advertising as OpenEvidence's monetisation model. The individual steps in that chain require their own evidence.
A clinician who registers and never returns contributes differently from one who uses the product repeatedly for a valuable task. A clinician who uses several competing tools contributes differently from one whose routine has become centred on a single service. Two products can have identical registration totals and substantially different businesses.
Even query volume is only an intermediate measure. Questions can differ in subject, commercial relevance and the context in which an advertisement could appropriately appear. More queries do not automatically mean proportionately more revenue, just as more registrations do not automatically mean proportionately more queries.
The commercial questions are therefore about retention, frequency, audience composition and monetisation. A cumulative account total cannot answer all four.
A large audience strengthens the opportunity, not every assumption
The October 2026 Johns Hopkins Medicine announcement describes majority daily use among US physicians and announces a collaboration with OpenEvidence. That is a consequential public positioning statement. Assessing the usage claim still requires its counting method.
Suppose, hypothetically, an audience is large but concentrated among occasional users. The business may have substantial room to increase engagement, but it has not already secured that future activity. Suppose instead that frequent use is concentrated in a narrower group. The service may be indispensable to that group while having less broad habitual adoption than an undifferentiated headline suggests.
Neither scenario is an assertion about OpenEvidence's private data. They illustrate why the distribution of activity matters alongside its total. A company can resolve the distinction with cohort retention, active-user definitions and frequency distributions rather than asking outsiders to choose the most favourable interpretation.
The more ambitious the valuation story becomes, the more useful those ordinary operating disclosures become.
Clinical trust creates a commercial constraint
Advertising can finance access that users would otherwise have to pay for. That is a coherent business model. Its success in clinical information depends on preserving confidence in how recommendations are produced and presented.
The commercial opportunity therefore comes with a design question: how clearly can a clinician distinguish sponsored material from the evidence supporting an answer? The question does not assume that advertising has distorted any particular OpenEvidence response. It identifies a condition that an advertising-supported clinical product needs to maintain as revenue grows.
If monetisation expands by increasing commercial exposure, the company should be able to demonstrate that the source selection and clinical answer remain trustworthy. If revenue expands through new products or customers, those businesses need their own adoption and economic evidence.
Clinical trust cannot simply be entered in a model as a permanent asset. It has to survive the product's evolving incentives and the user's repeated experience.
Competition can arrive through the workflow
The strongest competitive challenge need not come from an assistant that wins every benchmark. A rival may be easier to reach during an existing task, included in a contract or better suited to one specific clinical workflow.
This is an analytical possibility rather than a prediction about any named competitor. It explains why adoption at one point in time cannot establish permanent control of physician attention. A useful tool can remain widely respected while users divide their activity across several services.
OpenEvidence's defence would therefore need to be more substantial than having signed up a large audience first. Relevant questions include whether clinicians return without repeated acquisition effort, whether the product produces useful answers at an acceptable verification cost, and whether integration makes a workflow meaningfully better.
Product breadth can help, but it complicates measurement. Once an account serves multiple functions, a platform-wide activity figure should not be treated as evidence that every feature is equally established. The business can become broader while the headline becomes less specific.
The disclosures that would improve the discussion
Five pieces of information would make the valuation argument more concrete: clearly defined active clinicians; retention by registration cohort; activity by major workflow; revenue measured over stated periods; and the costs associated with delivering that activity.
These need not expose individual clinicians or commercially sensitive customer terms. Aggregated definitions and consistent reporting would already allow a more serious assessment than treating every new milestone as confirmation of every earlier claim.
For clinicians, the financing remains context. It does not establish that an answer is better supported or that a recommendation fits the patient in front of them. Readers assessing iatroX should likewise begin with how it works and its methodology, rather than assuming a company's commercial narrative settles a clinical question.
OpenEvidence may build a business capable of supporting the expectations attached to $15 billion. The clearest way to strengthen that case is to show how defined physician activity becomes durable revenue while clinical usefulness improves. The number on the cap table is already public. The operating definitions should catch up.
Frequently asked questions
Has OpenEvidence actually reached a $15 billion valuation?
Becker's reported chief executive confirmation of a $250 million financing at that valuation on 28 September 2026. A financing valuation reflects the terms and expectations of that transaction. It does not independently establish a particular level of clinical performance or future revenue.
Is the reported $300 million figure audited annual revenue?
The figure used here is Sacra's estimate of annualised revenue in July 2026. It should retain that description. It is neither presented as an audited completed-year result nor silently relabelled as recurring subscription revenue.
Why do user definitions matter to an advertising-supported business?
Because registration, repeated activity and commercially relevant attention are different stages. Clear definitions help readers assess how audience reach could translate into revenue and how durable that revenue might be. They also prevent one broad user number from substituting for evidence about retention and engagement.